Image
Recommendation
Assessment of markers (ER, PR and HER2) #2
Assess the ER, PR and HER2 status of all invasive breast cancers using standardised and quality-assured immunohistochemical techniques and report the results quantitatively. Ensure receptor status test results are available and recorded at the preoperative and postoperative multidisciplinary team meetings when systemic treatment is discussed.
Assess the ER status of all invasive breast cancers using standardised and quality-assured immunohistochemical technique and report the results quantitatively;
Assess the PR status of all invasive breast cancers using standardised and quality-assured immunohistochemical techniques and report the results quantitatively;
Assess the HER2 status of all invasive breast cancers using standardised and quality-assured techniques and report the results quantitatively; Ensure that the ER, PR and HER2 statuses are available and recorded at the preoperative and postoperative multidisciplinary team meetings when systemic treatment is discussed
How this guidance was developed
This recommendation was adopted from the NICE 2018 guidelines (UK). This recommendation was adopted from three source recommendations based on a systematic review of the evidence conducted to September 2017. Although all three source recommendations used wording (‘Assess’) indicative of a strong recommendation (using GRADE methods) by the source guideline authors, the NICE evidence review indicates that these recommendations are based on expert consensus due to a lack of evidence. The source recommendations were combined into one recommendation.
Assessment of markers (ER, PR and HER2) #2
Recommendation
Assess the ER, PR and HER2 status of all invasive breast cancers using standardised and quality-assured immunohistochemical techniques and report the results quantitatively. Ensure receptor status test results are available and recorded at the preoperative and postoperative multidisciplinary team meetings when systemic treatment is discussed.
Principles in action
Multidisciplinary care
This recommendation was adopted from the NICE 2018 guidelines (UK). This recommendation was adopted from three source recommendations based on a systematic review of the evidence conducted to September 2017. Although all three source recommendations used wording (‘Assess’) indicative of a strong recommendation (using GRADE methods) by the source guideline authors, the NICE evidence review indicates that these recommendations are based on expert consensus due to a lack of evidence. The source recommendations were combined into one recommendation.